Public observer slides

Lead team presentation Ixekizumab for the treatment of moderate to severe plaque psoriasis (STA)

1st Appraisal Committee meeting Committee B, 5th October 2016


Lead team: Ray Armstrong, Sanjeev Patel and Nigel Westwood

Company: Eli Lilly

Chair: Amanda Adler

Evidence Review Group: Kleijnen Systematic Reviews Ltd NICE technical team: Anna Brett, Jasdeep Hayre

Summary of evidence and key issues



Ixekizumab (Taltz) Eli Lilly

Psoriasis	A common chronic inflammatory disease characterised by red, thick and scaly plaques on the skin Plaque psoriasis the most common form of the disease
Mechanism of action	Antibody that inhibits IL-17A (interleukin-17A, a pro-inflammatory cytokine)
Marketing authorisation	"moderate to severe plaque psoriasis in adults who are candidates for systemic therapy"
Administration & dose	 Subcutaneous injection 160mg at week 0, followed by 80mg every 2 weeks until week 12 (induction) After week 12, 80mg every 4 weeks (maintenance)

Patient and professional feedback

- Psoriasis typically follows a relapsing and remitting course
- Can be a debilitating disease that impacts all aspects of life, physically, psychologically and socially
- 75% patients report burdensome symptoms (itching, redness, scaling, flaking)
- Clearance of symptoms with low or manageable side effects is important to people with psoriasis
- Access to treatments and a wide choice available in pathway if treatments fail
- Need for an alternative for those with failure of 1st biologic, or who lose response, are contraindicated or intolerant
- No additional resources required for ixekizumab
- Similar position in treatment pathway to secukinumab (after standard systemic therapies and/or phototherapy have failed)

Decision problem - comparators

Acitretin, fumaric acid esters, phototherapy missing from submission

NICE scope	Company submission				
1) If non-biologic systemic treatment or phototherapy suitable:					
 Systemic non-biological therapies (including acitretin, ciclosporin, fumaric acid esters, methotrexate) Phototherapy with ultraviolet (UVB) radiation 	 Systemic non-biological therapies (including ciclosporin and methotrexate) 				
2) For people with severe psoriasis for whom non-biologic systemic treatment or phototherapy is inadequately effective, not tolerated or contraindicated:					
 TNF-α inhibitors (etanercept, infliximab, adalimumab) Ustekinumab Secukinumab Best supportive care TNF-α inhibitors (etanercept, infliximab, adalimumab) Ustekinumab Best supportive care Best supportive care 					
Company justification for difference					
 Insufficient data for fumaric acid, acitretin or phototherapy for analysis Ixekizumab position in pathway aligned to biologic therapies (population 2) - 					

• Ixekizumab position in pathway aligned to biologic therapies (population 2)

5

Decision problem – ERG critique

Population	No consensus on definition of disease severity ('moderate to severe') using PASI thresholds:				
	 Company: 'moderate to severe'; PASI				
	 NICE (previous TAs): 'severe'; PASI				
	Has implications for generalisability of trial population and economic analysis				
Comparators	Inappropriate to exclude comparators in scope				
	At clarification Company: it did not search UVB studies in literature review; 'limited relevance' due to position in pathway. ERG: studies with UVB might be relevant for NMA estimates				
Outcomes	Signs on the face could have a psychological impact on patients				
	Excluding this outcome makes it difficult to draw conclusions from clinical evidence for those with signs on face				
Psoriasis Area and Severity Index (PASI); Dermatology Life Quality Index (DLQI); Network Meta-analysis (NMA) 6					

Existing NICE guidance

Moderate to severe disease, candidates for phototherapy or systemic therapy							
Phototherapy (UVB radiation		Ciclos	sporin	Acitretin	Fumaric acid		Ixekizumab?
<u>CG153</u>	<u>CG153</u>	CG	<u>153</u>	<u>CG153</u>	este	rs^	
Severe disease (PASI <u>>10</u> and DLQI >10) and no response, intolerance or contraindication to standard systemic therapies							
Adalimumab ★	Etanercept ★	Ustekini O			mab Ix		kekizumab?
<u>TA146</u>	<u>TA103</u>	<u>TA18</u>	<u>30</u>	<u>TA350</u>			
Very severe disease (PASI <u>></u> 20 and DLQI >18) and no response, intolerance or contraindication to standard systemic therapies							
Infliximab ★				lxe	kizum O	ab?	
	<u>TA134</u>						
*Not licensed but used for moderate psoriasis							

★: Tumour Necrosis Factor-alpha inhibitors ۞: Interleukin inhibitors

• Where would ixekizumab fit in the treatment pathway?

Company's clinical evidence 3 key clinical trials

Trials	UNCOVER-1, UNCOVER-2, UNCOVER-3
Design	Phase III; multicentre; randomised; double-blind
Population	Adults with moderate to severe plaque psoriasis (who are candidates for phototherapy and/or systemic therapy) UNCOVER-1: 1,296; UNCOVER-2: 1,224; UNCOVER-3: 1,346
Intervention	Ixekizumab 160mg starting dose then 80mg q2W or 80mg q4W*
Comparator	UNCOVER-1 placebo UNCOVER-2 placebo; etanercept 50mg twice weekly UNCOVER-3 placebo; etanercept 50mg twice weekly
Primary Outcomes	 PASI 75 response rate at week 12 sPGA (0,1) response rate at week 12 with at least 2-point improvement from baseline
Duration	5 years (including long-term safety and efficacy follow-up)
*Licensed dose	e: 160mg at week 0, 80mg q2W until week 12 , then 80mg q4W.

q2W, every 2 weeks; q4W, every 4 weeks; PASI, Psoriasis Area and Severity Index; sPGA, static Physician Global Assessment 8

Clinical evidence – ERG critique Generalisability of UNCOVER trials to NHS patients

Thresholds	Source	Definition			
PASI <u>></u> 12 + body surface area <u>></u> 10% + sPGA <u>></u> 3	UNCOVER trial eligibility criteria	Moderate to severe disease and candidates for phototherapy and/or systemic therapy			
PASI <u>></u> 10 + DLQI >10	Company definition	Moderate to severe disease			
	NICE (previous technology appraisals)	Severe disease			
PASI > 10 (or 12)	ERG's clinical experts	Moderate to severe disease for biological therapies			
Ixekizumab marketing authorisation					
" for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy"					

How is moderate/severe psoriasis defined in clinical practice in England?
Do the patients in the UNCOVER trials represent moderate to severe psoriasis as defined in the NHS?

PASI, Psoriasis Area and Severity Index (higher scores = more severe disease); sPGA, static Physician Global Assessment; DLQI, Dermatology Life Quality Index

Company's clinical evidence Results – UNCOVER-1 and -2

Response rates (ITT) at week 12 – ixekizumab higher (p=<0.001)

UNCOVER-1		lxekizu	Ixekizumab q2W		Ixekizumab total (q2W & q4W)	
			n=433		n=865	n=431
75	%		89.1%	85.9%		3.9%
PASI	Odds Ratio (95% CI)		224 (125, 401)	N/A		N/A
UNCOVER-2		lxekizumab q2W	Ixekizumab total (q2W & q4W)		Etanercept	Placebo
		n=351	n=351		n=358	n=168
	%	89.7%		83.7%	41.6%	2.4%
PASI75	OR vs. Pbo (95% Cl)	997 (173, 5745)	289 (88, 945)		30.7 (10.8, 87.2)	N/A
۶4	OR vs. Eta (95% Cl)	13.3 (8.7, 20.3)	(5.	7.6 6, 10.3)	N/A	N/A

ITT, Intention-to-Treat; q2W, every 2 weeks; q4W, every 4 weeks; PASI, 10 Psoriasis Area and Severity Index; CI, confidence interval

Results – UNCOVER-3


Response rates (ITT) at week 12 – ixekizumab higher (p=<0.001 for all comparators)

UNCOVER-3		lxekizumab q2W	Ixekizumab total (q2W & q4W)	Etanercept	Placebo
		n=385	n=771	n=382	n=193
	%	87.3%	85.7%	53.4%	7.3%
PASI 75	OR vs. Pbo (95% Cl)	72.3 (36.1, 145)	70.5 (37.8, 131)	13.7 (7.6, 24.7)	N/A
A	OR vs. Eta (95% Cl)	6.5 (4.4, 9.5)	5.6 (4.2, 7.5)	N/A	N/A

• Is ixekizumab more clinically effective than placebo and etanercept?

ITT, Intention-to-Treat; Eta, Etanercept; Pbo, Placebo; q2W, every 2 weeks; q4W, every 4 weeks; PASI, Psoriasis Area and Severity Index; OR, odds ratio; CI, confidence interval 11

Subgroup analysis – baseline severity Treatment effect consistent



IXE, Ixekizumab; PASI, Psoriasis Area and Severity Index; ITT, Intention-to-Treat; DLQI, Dermatology Life Quality Index; q4W, every 4 weeks; q2W, every 2 weeks 12

Subgroup analysis – previous biologic treatment Treatment effect consistent

Proportion of patients achieving PASI 75 at week 12					
UNCOVER-2	IXE q2W	IXE q4W	Etanercept	Placebo	
Biologic-naïve (n=936)	88.8%	78.6%	44.3%	3.2%	
Prior biologic therapy (n=288)	92.9%	74.1%	30.3%	0%	

Proportion of patients achieving PASI 75 at week 12

UNCOVER-1, -2, -3 ITT, Placebo-Controlled. Previous biologic therapy n=883

Discontinued previous biologic therapy due to inadequate response

IXE q2W		IXE q4W		Placebo	
Discontinued previous biologic therapy due to other reasons					
IXE q2W		IXE q4W		Placebo	

PASI, Psoriasis Area and Severity Index; IXE, Ixekizumab; q4W, every 4 weeks; q2W, every 2 weeks; ITT, Intention-to-Treat¹³

Subgroup analysis – ERG critique Summary of results

- Consistently high PASI 75 response rates shown for ixekizumab compared with placebo regardless of previous treatment with non-biologic systemic treatments or biologics
- Company provided additional information at clarification that showed low heterogeneity of effectiveness across the UNCOVER studies

• Is clinical effectiveness of ixekizumab modified by baseline disease severity and previous treatment?

Clinical evidence – network meta-analysis

Trial populations generally similar

Scenario analysis conducted for comparison with non-biologics

	Company	ERG
Baseline PASI score	Entry criteria 'largely consistent' with PASI ≥10-12 Baseline PASI score mean: 21.1 (standard deviation 2.8), median: 20.4	Agrees no major imbalances of baseline characteristics, although some patients had PASI <10
Previous treatment	Varied Not all patients had inadequate response or contraindicated to standard systemic therapies	Some trials had more patients who had had biologic therapy before Potential bias introduced as NICE guideline on <u>psoriasis</u> says effectiveness is lower when used as 2 nd biologic treatment in a sequence

Company's clinical evidence Results of network meta-analysis, base case, absolute probabilities of achieving PASI 75

Treatment	Probability	95%	o Crl
Ixekizumab 80mg q2W			
Ixekizumab 80mg q4W			
Secukinumab 300mg	81.8%	74.9%	88.1%
Infliximab 5mg/kg	81.1%	72.6%	88.1%
Ustekinumab 45mg	71.0%	62.2%	78.8%
Ustekinumab 90mg	75.1%	66.2%	82.7%
Ustekinumab 45mg<100kg & 90 mg>100kg	64.4%	54.0%	73.9%
Adalimumab 80mg/40mg EOW	57.5%	46.4%	68.2%
Etanercept 25mg BIW & 50mg qW	41.3%	30.3%	52.8%
Placebo	4.7%	3.1%	6.6%

• Is ixekizumab more effective than other biologics?

q2W, every 2 weeks; q4W, every 4 weeks; EOW, every other week; BIW, twice weekly; PASI, Psoriasis Area and Severity Index; CrI, credible interval

Cost effectiveness

Company's model Consistent with NICE reference case

Туре	Markov state transition		
Population	Patients who had failed on prior systemic treatments and eligible for 1 st line biologic therapy (as per NICE guidance)		
Comparators	 Biologic therapy only, 1st line within a treatment sequence Etanercept Ustekinumab Adalimumab Secukinumab Infliximab 		
Time horizon	Lifetime (44.0 years to 99.9 years) Patients expected to spend >10 years on active treatment		
Cycle length	1 month, captures induction periods when patients switch to a new treatment		
Measure of health effects		Quality-Adjusted Life Year	
Discounting of utilities & costs		3.5%	
Perspective		NHS/PSS 18	


Company's model – ERG critique Population inconsistent

- Company: 'Patients who had failed on prior systemic treatments and eligible for 1st line biologic therapy' (as per NICE guidance)
- Model results do not reflect biologic-naïve population because UNCOVER trials and indirect evidence included in network metaanalysis include patients who:
 - Have never had systemic treatments
 - Have had prior biologics
- Company explain that it modelled ixekizumab as 1st of 3 biologic treatments and only 26.4% UNCOVER patients had prior biologics
- ERG consider model population to be 'a population for whom biologic therapy is considered'

• Can the model be used to inform decisions on all the populations in the decision problem? If not, which populations?

PASI, Psoriasis Area and Severity Index; DLQI, Dermatology Life Quality Index 19

Company's model - structure



Company's model – ERG critique Health states

- Model developed around PASI response: approach is common in disease area but there is a drawback
- Health states should be homogenous (in terms of quality of life and resources use)
- Because health states are based on <u>relative</u> PASI response this may not be the case
- Patients in specific PASI relative response states may differ in quality of life and resource use
- Model may not capture true impact of treatment on quality of life and resource consumption
- This may bias comparative effectiveness (QoL/resource use PASI 75 on 1 treatment may not be the same as PASI 75 on another treatment)

PASI, Psoriasis Area and Severity Index; QoL, Quality of life

Company's model Treatment sequences

Sequence	1 st line	2 nd line	3 rd line	4 th line
1A	Ixekizumab			Best
1B	Adalimumab		Infliximab	Supportive Care
1C	Etanercept 50mg	Ustekinumab 90mg		Cale
1D	Infliximab	Song	Adalimumab	
1E	Secukinumab			
1F	Ustekinumab 45mg	Adalimumab	Infliximab	
1G	Ustekinumab 90mg	Auaiimumab		

Treatments	NICE rule – stop if inadequate response after:
Infliximab	10 weeks
Etanercept, Secukinumab	12 weeks
Adalimumab, Ustekinumab	16 weeks

Note that ustekinumab dose is weight based: 45mg for those with a weight of less than 100kg; 90mg for those who weight more than 100kg

Company's model – ERG critique Treatment sequences

- Approach of comparing treatment sequences better than comparing single treatments
- Non-biologics not included, but this is reasonable if patients have failed these; however, phototherapy may still be an option
- Modelling should include most optimal treatment sequence not just most widely used (based on market share)
- Plausible to position ixekizumab in the sequence as a 2nd biologic treatment - clinicians suggest it will probably be used 2nd because doctors have more experience with other biologics
 - Do the treatment sequences reflect NHS practice?
 - Would ixekizumab be used as 1^{st} or 2^{nd} line biologic?

Company's model Transition probabilities

Induction to maintenance	PASI 75 response Proportion of patients achieving PASI 75 response at 12 weeks in network meta-analysis (ITT population)
Maintenance to treatment stopping	All cause, constant annual rate of 20% (based on BADBIR, supported by previous appraisals), converted to monthly drop out rate and applied to each cycle <i>ERG: All cause constant annual rate not plausible or</i> <i>constant over time, but evidence for treatment-specific</i> <i>rates limited so equal rates for different treatments</i> <i>appropriate</i>
Treatment stopping to best supportive care	As above, or inadequate response to 3 rd treatment after induction Level of response equal to placebo level of response in network meta-analysis
Any state to death	Probability taken from national mortality life tables (gender-weighted, age-dependent) Risk applied in all treatment states

Company's model – ERG critique Transition probabilities – treatment effectiveness

- Assumed treatment response did not vary with position in sequence
 - Did not include decrease in effectiveness of subsequent biologics in base case
 - Clinical expert suggests effect modification may not happen if subsequent biologics have different modes of action
- Response based on intention-to-treat populations network meta-analysis
 - Inconsistent with health utility inputs (sub-population of patients in UNCOVER trials with DLQI >10 used to derive health utilities)
 - In DLQI >10 sub-population, treatment response was lower
- Response to best supportive care placebo arm of UNCOVER trials, but:
 - Best supportive care can include systemic treatments that were prohibited in placebo arms of UNCOVER trials (for example, methotrexate)
 - Inconsistent with cost inputs (systemic treatment costs included)

 Which population should be used to estimate effectiveness; intention-to-treat or DLQI >10 subgroup?

Company's model Inputs: Health utilities – summary

- Health related quality of life expressed in terms of change from baseline EQ-5D-5L associated with PASI response
- EQ-5D-5L collected in 3 UNCOVER trials baseline + 12 weeks
- Change in utility calculated for each patient, then pooled across treatment arms and stratified by PASI response
- Only utility data for patients with DLQI >10 used
- Utility gains only applied in maintenance period so health utilities assigned in same way for all treatments within sequence
- Utility assumed to be constant over time
- Company did not include disutility of adverse events in model

Company's model – ERG critique

Health utility values lower compared with previous TAs

PASI response category			50-74	75-89	90-99	100
	DLQI >10	0.01	0.10	0.13	0.14	0.15
lxekizumab UNCOVER	Total	0.01	0.07	0.08	0.10	0.10
	Excluding PASI 100					N/A
	Total	0.05	0.14	0.14	0.22	NR
Adalimumab TA146	DLQI <u><</u> 10	0.05	0.10	0.10	0.13	NR
	DLQI >10	0.06	0.18	0.18	0.31	NR
Etoporoopt TA 102	Total	0.05	0.17	0.19	0.21	NR
Etanercept TA103	4 th quartile DLQI	0.12	0.29	0.38	0.41	NR
Ustekinumab TA180	DLQI >10	0.04	0.17	0.22	0.25	NR
Secukinumab TA350	DLQI >10	0.11	0.19	0.23	0.26	NR
Infliximab TA134	4 th quartile DLQI	0.12	0.29	0.38	0.41	NR

TAs, Technology Appraisals; PASI, Psoriasis Area and Severity Index; DLQI, Dermatology Life Quality Index; NR, not reported 27

Company's model – ERG critique Inputs: Health utilities

Population – inconsistent	 Using population with DLQI >10 matches scope better but inconsistent with ITT population used for effectiveness; PASI response lower in DLQI >10 population: ERG agrees with using DLQI subset
 Which population 	on should be used for utility gains; ITT or DLQI >10?
Estimates of utility gains – uncertain	 Regression model (with baseline EQ-5D-5L & PASI response as covariates) used to convert EQ-5D-5L to utilities. Company did not provide model diagnostics: ERG unable to assess if model appropriate 'Last observation carried forward' used for those who stop treatment before end of induction. Unknown how many patients or why they stopped treatment
No utility gain applied in induction period – implausible	 Duration of induction phase differs between treatments; may impact on comparative effectiveness Rapid onset of response with ixekizumab; likely gives a conservative estimate of health utility gains

• When do people get the benefit of treatment? Should there be a utility gain in the induction period for ixekizumab?

Company's model Inputs: Costs – summary

- Treatment acquisition (ixekizumab PAS price, secukinumab no PAS, biosimilar list prices for infliximab and etanercept)
- Treatment administration, monitoring & best supportive care costs included
- Non-responders applied to induction period following stopping treatment, reflecting higher disease activity and worse health after not responding, set at £274 monthly
- Company excluded adverse events (non-melanoma skin cancer, other malignancies, severe infection) - included in company sensitivity and scenario analyses and ERG's base case
 - Should the cost of adverse events be included?

Company's model and ERG critique Inputs: Best supportive care costs

Drug cost	£1,251	
Inpatient admissions and outpatient care	£2,957	
Total annual cost (2014/15)	£5,082	
Cost applied per model cycle	£424	
Source: Fonia et al (2010)		

- Data on hospital resource use and drug usage collected 12 months prior to and 6 months following starting biologic treatment – reflect moderate to severe psoriasis without biologic treatment
- *ERG*: Estimates do not represent best supportive care after failure of many biologic treatments; costs of systemic non-biologic treatment included, but not likely to be given
- Resource use and costs for best supportive care uncertain
 Do the estimated costs of best supportive care reflect actual cost? If not, are the costs over- or under-estimated?

Company's base case – deterministic results, fully incremental (ixekizumab PAS, secukinumab list price)

Treatment	Total		Increments vs ETA		ICER
sequences	Costs	QALYs	Costs	QALYs	
ETA→UST90→INF 1C	£144,635	1.27	-	-	-
UST45→ADA→INF <i>1F</i>	£148,218	1.30	£3,583	0.04	Extendedly dominated
ADA→UST90→INF 1B	£148,350	1.32	£3,715	0.05	Extendedly dominated
UST90→ADA→INF 1G	£148,719	1.32	£4,083	0.06	Extendedly dominated
INF→UST90→ADA 1D	£150,350	1.33	£5,714	0.06	Extendedly dominated
IXE→UST90→INF 1A	£150,889	1.45	£6,254	0.18	£33,858
SEC→UST90→INF <i>1E</i>	£177,101	1.42	£32,466	0.15	Dominated by IXE

ETA, etanercept; UST45, ustekinumab 45mg; ADA, adalimumab; INF, infliximab; IXE, ixekizumab; SEC, secukinumab; UST90, ustekinumab 90mg

Company's scenario analyses results

Scenario	ICER vs. etanercept sequence unless stated
Company's base case (deterministic)	£33,858
1) Prior failure/contraindication to TNF- α inhibitor	ixekizumab dominant
2) Single treatment comparisons (no sequence)	£39,563
3) Comparison with non-biologic systemic therapy (methotrexate, ciclosporin, best supportive care)	£65,468 vs. methotrexate
5) Effect modification of previous biologic treatment	£38,034
6) Branded prices for etanercept and infliximab	£24,923
7) Utility gain assignment in induction period	£32,337
8) Including costs of adverse events	£32,932
10) Using a range of alternative utility sources	£16,109 to £47,235
11) Source of best supportive care costs	ixekizumab dominant
12) Varied best supportive care efficacy	£30,738 to £60,586

ERG's exploratory analyses – ERG's base case

- Different assumptions to company's base case:
 - Costs of adverse events included
 - Linear utility gains applied during induction period
 - Treatment sequence with ixekizumab as 2^{nd} biologic included (adalimumab \rightarrow ixekizumab \rightarrow infliximab)
- Fixed errors
 - Re-calculated adverse event unit costs, corrected error in adverse event rates
 - Re-calculated standard error for NHS reference costs (for probabilistic sensitivity analysis)
 - Corrected number of secukinumab administrations in maintenance period
- Probabilistic analysis as base case

ERG's base case – probabilistic results, fully incremental (ixekizumab PAS, secukinumab list price)

			· /
Treatment sequences	Company's ICER (ERG calculated)	ERG's ICER 1 st line IXE	ERG's ICER 2 nd line IXE
ETA→UST90→INF 1C	-	-	-
ADA→IXE→INF		£25,532	£25,532
1H	Not reported	vs ETA	vs ETA
UST45→ADA→INF	Extendedly	Dominated by	Dominated by
1F	dominated	ADA→IXE→INF	ADA→IXE→INF
ADA→UST90→INF	Extendedly	Dominated by	Dominated by
1B	dominated	ADA→IXE→INF	ADA→IXE→INF
UST90→ADA→INF	Extendedly	Dominated by	Dominated by
1G	dominated	ADA→IXE→INF	ADA→IXE→INF
IXE→UST90→INF	£32,541	£39,129	
1A	vs ETA	vs 2 nd line IXE	Excluded
INF→UST90→ADA	Extendedly	Dominated by	Dominated by
1D	dominated	IXE→UST90→INF	ADA→IXE→INF
SEC→UST90→INF	Dominated by	Dominated by	
1E	IXE→UST90→INF	IXE→UST90→INF	£730,630

34

ERG's base case – probabilistic results, pairwise comparison (ixekizumab PAS, secukinumab list price)

Treatment sequences	Company's ICER (ERG calculated)	ERG's ICER 1 st line IXE vs comparator	ERG's ICER 2 nd line IXE vs comparator
ETA→UST90→INF 1C	£32,541	£30,517	£25,532
ADA→IXE→INF 1H	Not reported	£39,129	-
UST45→ADA→INF 1F	£16,550	£15,024	Dominated
ADA→UST90→INF 1B	£17,460	£15,281	Dominated
UST90→ADA→INF 1G	£15,027	£13,147	Dominated
IXE→UST90→INF 1A	-	-	-
INF→UST90→ADA 1D	£602	Dominated	Dominated
SEC \rightarrow UST90 \rightarrow INF 1E	Dominated	Dominated	£730,630

ICER, incremental cost effectiveness ratio; ETA, etanercept; UST45, ustekinumab 45mg; ADA, adalimumab; INF, infliximab; IXE, ixekizumab; SEC, secukinumab; UST90, ustekinumab 90mg 35

ERG's scenario analyses results

Scenario	ICER: IXE 1 st line vs IXE 2 nd line sequence	ICER: IXE 2 nd line vs etanercept sequence
ERG's base case (probabilistic)	£39,129	£25,532
Using ITT population from UNCOVER x3 to estimate utility gains	£55,243	£36,314
Using treatment effectiveness data from patients with DLQI >10 in UNCOVER x3	£40,308	£26,499
Applying effect modification of previous biologic treatment	£35,514	£35,191
Increasing best supportive care costs by 20%	£32,673	£17,532
Decreasing best supportive care costs by 20%	£45,709	£33,352
Including alternative treatment sequence: Adalimumab \rightarrow Secukinumab \rightarrow Infliximab	£38,914	£25,423 36

Innovation

Company notes:

- Rapid onset of efficacy
- Improvements in difficult to treat areas
- Easy to use

British Association of Dermatologists notes:

 Different mode of action and extended activity of ixekizumab compared with secukinumab (another IL-17 inhibitor) because it binds to both IL-17 A and IL-17 F

Equality considerations

- Current disease severity criteria for biologics may discriminate:
 - PASI score can underestimate disease severity in those with black or brown skin
 - DLQI has limited validity in those not working, older people, and may miss anxiety and depression
- Self-injecting a barrier, particularly for those with phobias or poor hand mobility. Feedback from patients suggests people appear to cope, or find ways to cope, with administration methods, as long as there is treatment benefit

PASI, Psoriasis Area and Severity Index; DLQI, Dermatology Life Quality Index

Key issues for decision-making

- Where is ixekizumab in the treatment pathway? Would it be used as 1st or 2nd biologic?
- Do the patients in the UNCOVER trials represent moderate to severe psoriasis as defined in the NHS?
- Is ixekizumab more effective than placebo and etanercept?
- If so, regardless of disease severity and previous treatment?
- Can the model be used to inform decisions on all the populations in the decision problem? If not, which populations?
- Do the treatment sequences reflect NHS practice?
- Which population (intention-to-treat or DLQI >10 subgroup) should form the basis of estimates of effectiveness? For utility?
- When do people get the benefit of treatment? In induction period as well as in maintenance period?
- Should the model include the costs of adverse events?
- Are the estimated costs of best supportive care valid?
- Equalities, innovation and PPRS